Summary of the Conference Call for Lepu Medical Company Overview - **Company**: Lepu Medical - **Industry**: Medical Devices and Pharmaceuticals Key Points and Arguments Traditional Business Performance - Lepu Medical's traditional business remains stable, with cardiovascular devices and generic drugs showing steady performance. The expected profit for the basic business in 2025 is projected to reach between 1 billion to 1.2 billion CNY [2][4][5] - Operating cash flow has significantly improved, reaching 1 billion CNY in the first three quarters, with an annual forecast of 1.5 billion CNY [2][4] Aesthetic Medicine Segment - The aesthetic medicine segment has emerged as a new growth driver, with the "童颜针" (Youthful Needle) achieving nearly 100 million CNY in sales and entering 1,500 to 2,000 institutions [2][5][7] - New products like "热玛吉" (Thermage) and PDRN are expected to launch in the first half of next year, potentially boosting revenue further [2][5][7] Impact of Procurement Policies - The centralized procurement policy has put pressure on cardiovascular devices, but the company is managing dealer inventory and actively participating in procurement to mitigate impacts [2][6] - The coronary cutting balloon may face losses, but the auxiliary balloon is expected to compensate for this, maintaining overall balance [2][6] Market Expansion Strategy - Lepu Medical is aggressively expanding its aesthetic market using a "rural encircling cities" strategy, currently covering 80% of the targeted institutions and planning further expansion through partnerships with platforms like Meituan [2][7][19] Innovation in Drug Development - Significant progress has been made in innovative drug development, with drug 109 completing phase II clinical trials and plans to enter phase III next year. Multiple projects for weight loss, lipid reduction, and blood pressure management are also underway [2][10][11] Financial Performance - In Q3 2025, Lepu Medical reported a nearly 12% year-on-year revenue growth and a 176% increase in net profit, reaching 290 million CNY. Cumulative net profit for the first three quarters was 980 million CNY, slightly exceeding market expectations [3][4] Future Outlook - The company maintains a profit forecast of 1 billion to 1.1 billion CNY for 2025 and anticipates a stable business level in Q4 [4][5] - The aesthetic medicine sector is expected to generate close to 1 billion CNY in sales in 2026, with significant contributions from various products [9][21] Challenges and Opportunities - The aesthetic medicine sector faces challenges due to differing consumer logic and quality demands compared to traditional medical services. However, this also presents opportunities for providing scientifically reliable and easy-to-use products [23][20] Inventory Management - Lepu Medical is actively controlling dealer inventory to minimize stock levels in response to procurement policies, aiming to maintain inventory at one to two months' worth [24][25] Pricing Strategy - Despite recent price reductions by internet platforms, Lepu Medical is committed to maintaining its pricing strategy, offering a multi-tiered pricing approach to cater to different consumer segments [25][26] New Product Development - The company is advancing in the peripheral treatment field with new products like biodegradable occluders, which have shown promising clinical feedback [26][27] Management and Team Stability - The innovative drug team is stable and motivated, with regular clinical meetings and recruitment efforts to strengthen clinical operations [28][29] Conclusion - Lepu Medical is positioned for growth through its stable traditional business, expanding aesthetic medicine segment, and ongoing innovation in drug development, while effectively managing challenges posed by procurement policies and market dynamics. The company’s strategic focus on quality and market expansion is expected to drive future success.

Investment Rating - The investment rating for the retail industry is "Positive" (maintained) [1] Core Insights - The retail industry is experiencing a recovery in consumer spending, with a focus on high-quality brands and innovative products [6][27] - The approval of the first recombinant type I collagen by Juzi Biotech opens new opportunities in the medical beauty sector, enhancing the company's product matrix [22][24] - The report emphasizes the importance of emotional consumption trends driving growth in various segments, particularly in jewelry and cosmetics [27][28] Summary by Sections Retail Market Review - The retail index closed at 2288.31 points, up 0.46% for the week, underperforming the Shanghai Composite Index which rose by 2.88% [5][12] - Year-to-date, the retail index has increased by 2.21%, lagging behind the overall market performance [12][15] - Among retail segments, the professional chain sector saw the highest weekly increase of 1.96%, while the jewelry sector led year-to-date with a 23.33% rise [14][17] Industry Dynamics - Juzi Biotech's recombinant type I collagen product received NMPA approval, marking a significant advancement in the medical beauty market [22][23] - The product is the first of its kind in China, aimed at facial dermal filling and wrinkle correction, indicating strong growth potential in the high-value collagen injection market [22][24] Investment Recommendations - Focus on high-quality companies in the emotional consumption theme, particularly in the jewelry sector, with recommendations for brands like Laopu Gold and Chaohongji [6][27] - Emphasize retail companies that are actively transforming and exploring new strategies, such as Yonghui Supermarket and Aiyingshi [6][27] - Highlight domestic beauty brands with strong performance during promotional events, recommending companies like Juzi Biotech, Pola, and Maogeping [28][30] - Consider differentiated medical beauty product manufacturers and leading medical institutions, recommending companies like Aimeike and Kedi-B [28][30]

Group 1 - The company *ST Jinbi (SZ 002762) held its 22nd meeting of the fifth board on October 23, 2025, to review proposals including the confirmation of fair value changes and the provision for long-term investment impairment [1] - For the first half of 2025, the revenue composition of *ST Jinbi was 77.64% from the maternal and infant consumer goods sector, 21.03% from the medical beauty sector, and 1.33% from other sources [1] - As of the report date, *ST Jinbi's market capitalization was 2.7 billion yuan [1]

Core Viewpoint - In the first half of 2025, Sihuan Pharmaceutical turned a profit of 103 million yuan after three consecutive years of losses, with the medical beauty business contributing over 300 million yuan, becoming the largest profit source [1][4]. Group 1: Company Transformation and Financial Performance - Sihuan Pharmaceutical, established in 2001, was once a leader in the cardiovascular drug market but faced significant challenges from 2015 to 2024, resulting in a nearly 90% drop in market value [3]. - The company announced a strategic shift in 2020, moving from a focus on generic drugs to medical beauty and innovative drugs [3][4]. - By the first half of 2025, the medical beauty segment generated 585 million yuan in revenue, surpassing the revenue from generic drugs for the first time [6][7]. Group 2: Medical Beauty Business - The medical beauty business is now the flagship segment for Sihuan Pharmaceutical, with expectations of reaching 1 to 1.2 billion yuan in revenue for the year [6][7]. - The company has expanded its product offerings through acquisitions and partnerships, covering various categories in the medical beauty sector, with over 30 approved products [7][8]. - Sihuan's reliance on botulinum toxin remains significant, contributing approximately 80% of its medical beauty revenue, but this is expected to decrease as new products are launched [8]. Group 3: Innovative Drug Development - Sihuan Pharmaceutical has been involved in innovative drug development since 2008, but its contribution to overall revenue remains low, accounting for less than 5% in the first half of 2025 [11][12]. - The company has three commercialized innovative drugs, with only one, Annelazole, generating revenue [11][12]. - The competitive landscape for innovative drugs is intense, with multiple companies vying for market share in similar therapeutic areas [13][14].

Core Viewpoint - Four Seasons Pharmaceutical is undergoing a significant transformation, shifting from a traditional generic drug company to focusing on aesthetic medicine and innovative drugs, with recent strategic moves indicating a recovery and growth potential [2][5][20]. Group 1: Recent Developments - In October 2025, Four Seasons Pharmaceutical completed two major actions: acquiring equity in a Swiss aesthetic medicine company and spinning off its subsidiary Xuan Zhu Bio to list on the Hong Kong stock market, with Xuan Zhu's stock price increasing over 400% in eight trading days, reaching a market value of over 30 billion HKD [2]. - The company reported a profit of 103 million CNY in the first half of 2025, marking its first profit after three consecutive years of losses, with the aesthetic medicine segment contributing over 300 million CNY [5]. Group 2: Business Transformation - Four Seasons Pharmaceutical has shifted its focus from primarily generic drugs to aesthetic medicine and innovative drugs since 2020, with aesthetic medicine now being the largest profit source [5][7]. - The aesthetic medicine revenue reached 585 million CNY in the first half of 2025, surpassing generic drug revenue for the first time, with expectations of reaching 1 to 1.2 billion CNY for the full year [7][8]. Group 3: Market Position and Competition - The company has expanded its aesthetic medicine revenue from 26.87 million CNY in 2020 to 744 million CNY in 2024, narrowing the gap with established players in the industry [8]. - Four Seasons Pharmaceutical's aesthetic medicine products have been approved, with over 30 products in categories such as fillers and skin management, although it remains heavily reliant on botulinum toxin, which accounts for about 80% of its aesthetic medicine revenue [10][11]. Group 4: International Expansion - The company is also pursuing international expansion, having invested in the Swiss company Suisselle, which offers promising products and a global sales network [11]. - Previous international acquisitions include the full acquisition of Genesis Biosystems in the U.S. in 2021, allowing entry into the American market [12]. Group 5: Innovative Drug Business - Four Seasons Pharmaceutical has been involved in innovative drug development since 2008, but its innovative drug revenue remains low, accounting for less than 5% of total revenue in the first half of 2025 [15][16]. - The company has three commercialized innovative drugs, with only one, Annelazole, generating revenue, facing significant competition in the proton pump inhibitor market [16][17]. Group 6: Future Outlook - The company plans to further focus on aesthetic medicine as it prepares for the spin-off of its diabetes-focused subsidiary, Huisheng Bio, which may lead to a more streamlined business model [13]. - The innovative drug pipeline includes over ten candidates, but the competitive landscape in areas like oncology and NASH is crowded, posing challenges for future growth [19][20].

Core Viewpoint - The approval of the first injectable recombinant collagen product by the company marks a significant milestone in its product matrix, which now includes aesthetic injection products, post-surgery repair dressings, and functional skincare [1] Group 1: Product Approval and Market Potential - The newly approved recombinant type I α1 collagen lyophilized fiber is intended for facial dermal tissue filling to correct dynamic wrinkles, including frown lines, forehead lines, and crow's feet [1] - The Chinese aesthetic injection market is projected to reach CNY 147 billion by 2027, with the injectable collagen segment expected to grow to CNY 16.8 billion, indicating high growth potential [2] - Currently, there are four approved facial injectable recombinant collagen products in China, including the company's product and others from Jinbo Biotech [2] Group 2: Competitive Landscape and Channel Advantages - The company's product competes with Jinbo Biotech's offerings, which also target the dermal layer for wrinkle filling, suggesting future competition in eye and facial anti-aging scenarios [2] - The company has a strong channel advantage through its established brand recognition and deep distribution network in the aesthetic market, which is expected to enhance the market potential of the new injectable products [2] Group 3: Future Product Pipeline - The company has two additional injectable collagen products in the approval stage, with expected approval timelines in December 2024 and August 2025, which will further enrich its aesthetic product matrix [3] - These upcoming products will cover a range of anti-aging scenarios from dynamic wrinkle improvement to overall skin texture enhancement [3] Group 4: Financial Outlook and Ratings - The company maintains a "Buy" rating with a target price of HKD 58.35, despite a projected decline in online sales for its brand, which may affect overall revenue growth [4] - The company's revenue growth forecast for 2025 has been adjusted down to 12%, with a long-term CAGR for its brand's revenue growth revised from 26% to 14.5% [4]

Core Viewpoint - The company has received approval from the National Medical Products Administration for its self-developed "Recombinant Type I α1 Collagen Freeze-Dried Fiber," marking a significant advancement in the medical aesthetics sector and enhancing its competitive position in the market [1]. Industry Summary - The market for recombinant collagen in China is projected to reach 54.7 billion yuan by 2025, with the medical aesthetics segment expected to grow to 7 billion yuan, driven by high biocompatibility and low allergenic risk [2]. - The company is positioned as the second domestic entity to receive approval for recombinant collagen, allowing it to benefit from industry expansion [2]. Company Summary - The company's recombinant collagen product is designed to improve skin structure and reduce dynamic wrinkles, showcasing its technological advantages and creating a barrier to entry for competitors [1]. - Despite short-term sales fluctuations in skincare products due to reduced collaborations, the company maintains strong brand recognition and product efficacy, with expectations for recovery through optimized channel structures and scientific marketing [2]. - The company plans to expand the application of recombinant collagen beyond skincare and medical aesthetics to include hair growth and whitening, while also exploring international market opportunities [2]. - Revenue forecasts for 2025-2027 have been adjusted to 6.917 billion, 8.540 billion, and 10.419 billion yuan respectively, with net profits projected at 2.452 billion, 2.989 billion, and 3.603 billion yuan [2].

Core Viewpoint - The article emphasizes the importance of standardized clinical trials in the medical aesthetics industry, highlighting the need for scientific design, regulatory compliance, and reliable data to ensure the clinical value of innovative products [2]. Group 1: Clinical Trial Quality Management - The "Good Clinical Practice (GCP)" provides a unified standard for the industry, addressing the increasing complexity and compliance requirements of clinical trials in the medical aesthetics field [2]. - A special forum on "Clinical Trial Quality Management" was established to systematically analyze the core points of GCP and discuss the implementation and regulatory requirements of medical aesthetics-related trials [2]. Group 2: Forum Details - The second forum on the medical aesthetics industry was successfully held, with the next forum scheduled for October 31 to November 2, 2025, at the Beijing Yinhai International Conference Center [4]. - The agenda for the Clinical Trial Quality Management forum includes various presentations from experts in the field, covering common issues in clinical trials, high-quality research design, collaboration for quality trials, and ethical review from a legal perspective [5]. Group 3: Participants - The forum is expected to attract a diverse group of participants, including senior lawyers, representatives from medical device and aesthetics companies, clinical doctors, researchers, investment institutions, and regulatory experts [7].

Investment Rating - The report maintains a "Buy" rating for the company [2][16]. Core Insights - The approval of the first recombinant type I natural sequence collagen facial injection product in China marks a significant milestone for the company, enhancing its competitive position in the medical aesthetics market [7]. - The new product is expected to drive revenue growth and reshape the competitive landscape in the collagen product category, showcasing the company's technological and industrial capabilities [7]. - The company has demonstrated strong revenue growth across its product lines, with notable performance from its flagship products and new launches [7]. Financial Data and Profit Forecast - Projected revenue growth from 2023 to 2027 shows a significant increase, with revenues expected to rise from 3,524 million RMB in 2023 to 10,691 million RMB in 2027, reflecting a compound annual growth rate (CAGR) of approximately 49% [6][8]. - The net profit attributable to the parent company is forecasted to grow from 1,452 million RMB in 2023 to 3,726 million RMB in 2027, with a CAGR of around 23% [6][8]. - The company's gross margin is expected to remain stable, averaging around 82% over the forecast period [6]. Product Performance and Market Position - The flagship product, "可复美," generated revenue of 25.4 billion RMB in the first half of 2025, representing a year-on-year growth of 22.7% [7]. - The company has successfully launched new products that have gained market recognition, contributing to overall revenue growth [7]. - Direct sales channels have shown strong growth, with direct sales revenue reaching 23.3 billion RMB in the first half of 2025, up 26.5% year-on-year [7].

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company has successfully obtained approval for its self-developed "Recombinant Type I α1 Collagen Freeze-Dried Fiber," marking it as the first of its kind in China, with various specifications suitable for facial dermal tissue filling [2] - The recombinant collagen market in China is projected to reach 54.7 billion yuan by 2025, with the medical aesthetics market expected to grow to 7 billion yuan, indicating significant growth potential for the company [3] - The company is positioned as the second domestic enterprise to receive approval for recombinant collagen, allowing it to benefit from industry expansion [3] - The skincare segment is currently facing short-term sales fluctuations but is expected to stabilize and recover through optimized channel structures and strong brand recognition [4] Summary by Sections Medical Aesthetics - The company's recombinant collagen product showcases technical advantages and strengthens its leading position in the market, with a focus on improving skin structure and reducing dynamic wrinkles [3] - The product's unique formulation and research barriers enhance its market competitiveness [3] Skincare Products - Short-term sales have been impacted by a reduction in collaboration with influencers, but the brand's strength and product recognition remain robust [4] - The company aims to recover sales through channel optimization and continued consumer confidence driven by scientific marketing [4] Financial Projections - Revenue forecasts for 2025-2027 are adjusted to 6.917 billion, 8.540 billion, and 10.419 billion yuan respectively, with net profits projected at 2.452 billion, 2.988 billion, and 3.603 billion yuan [5] - The earnings per share (EPS) for the same period are expected to be 2.29, 2.79, and 3.36 yuan, with corresponding price-to-earnings (PE) ratios of 17, 14, and 11 times [5][8]